Keyword: Department of Health and Human Services (HHS)
The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.
J&J's CEO said this week the pharma industry needs to police itself on pricing. Days later, his company raised prices on two dozen drugs.
The president called advisers for a special meeting on drug prices after a new round of hikes from many industry players, Politico reports.
More than half of industry respondents in a GlobalData survey said pricing remains pharma's top concern in 2019.
The Trump administration's proposal to lower Medicare Part B drug prices has been met with plenty of pushback—and it's not just coming from pharma.
A number of drug pricing proposals remain up in the air heading into 2019, a year that should prove to be important for the evolving issue.
The government is riled up about drug prices and promising to drive them down, but a CMS report shows retail drug spending grew just 0.4% last year.
Zeroing in on the spread between drug prices in the U.S. and elsewhere, two lawmakers have released the latest proposal to try to keep a lid on prices.
Pfizer became the center of a drug pricing controversy this summer and delayed dozens of price hikes. Now it's ready to raise prices again in January.
Who wants drug prices in ads? Older people, that’s who.